Research programme: anticancer antibodies - Roche/XencorAlternative Names: Research programme: anticancer antibodies - Xencor/Roche
Latest Information Update: 29 Apr 2008
At a glance
- Originator Roche; Xencor
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jan 2006 Xencor and Roche have extended their collaborative research agreement to co-develop anticancer antibodies for Cancer
- 12 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)